| MRCGX | VEXPX | MRCGX / VEXPX | |
| Total Expense Ratio | 1.92 | 0.44 | 436% |
| Annual Report Gross Expense Ratio | 1.92 | 0.44 | 436% |
| Fund Existence | 10 years | 58 years | - |
| Gain YTD | -7.547 | 7.064 | -107% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 3000 | 83% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 678M | 20.5B | 3% |
| Annual Yield % from dividends | 0.00 | 0.37 | - |
| Returns for 1 year | -13.73 | -6.50 | 211% |
| Returns for 3 years | -9.24 | 18.47 | -50% |
| Returns for 5 years | -31.40 | -3.56 | 882% |
| Returns for 10 years | -17.24 | 34.74 | -50% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JEPQ | 58.47 | 0.30 | +0.52% |
| JPMorgan Nasdaq Equity Premium Inc ETF | |||
| XMPT | 21.83 | 0.08 | +0.37% |
| VanEck CEF Municipal Income ETF | |||
| NAUG | 29.43 | 0.10 | +0.34% |
| Innovator Growth-100 Pwr Buffr ETF - Aug | |||
| IWDL | 43.23 | N/A | N/A |
| ETRACS 2x Leveraged US Value Fctr TR ETN | |||
| IHE | 83.32 | -0.86 | -1.02% |
| iShares US Pharmaceuticals ETF | |||